Tag: revance therapeutics

February 6, 2020

Revance Receives FDA Acceptance of License Application for Frown Line Treatment

Revance announced that the Biologics License Application (BLA) for its frown line treatment has been accepted for review by the...
November 3, 2016

Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis

Revance Therapeutics, a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of...
December 24, 2015

Revance Therapeutics Reports Interim Efficacy and Safety Results from Phase 2 Clinical Trial

Revance Therapeutics, Inc. (NASDAQ:RVNC) has reported interim efficacy and safety results from a Phase 2 clinical trial of the RT001...